You run the company.
We run the round.
Companies hire us for three outcomes: wider mandate-fit coverage, a raise that keeps pace between gates, and a close that leaves a stronger institutional book. We create the interest, run distribution and follow-through, and free teams to stay on the science.
We run distribution through close.
A stronger institutional cap table and real optionality: mandate-fit coverage that opens more paths in this round and the next. Targeting rests on proprietary investor intelligence mapped across clinical-stage biotech.
A smoother process that does not consume the team, with data-led decisions each day and a hard cap of two live mandates. We own distribution, follow-through, and close while your operators stay on the science.
Capital follows disciplined pace.
Decades of capital markets execution.
With you to wired capital.
Investment case prepared to institutional standard: science, development path, financing logic, and the questions a committee will ask. Built to hold in underwriting,
Investors matched to how they underwrite clinical risk. Distribution aimed at names that can actually sit on the round and the cap table you want to build.
Warm, sequenced introductions with context attached. Follow-through owned by the process so every live thread has a dated next step and does not land back on the operating team.
Live conversations managed through to a decision. Objections answered, next steps dated, and commitments worked until capital is received.
Founder and Managing Director of Flusso. Trained in medicine. Leads every fundraising mandate.
Over four decades on Wall Street, beginning at Salomon Brothers. $1B+ personally raised.
25 years in US tech, early at Yelp, LinkedIn, and Skype. Active VC at K2X Capital and venture builder.
Built for clinical-stage rounds.
→ Clinical-stage biotech (and closely adjacent life sciences), US-based
→ Raising $10M+ on a defined timeline, capital mapped to a clear next value step
→ Data and financing story that can withstand institutional underwriting
→ Team that will keep development moving while the raise is run as a process
→ Operators who want wider, mandate-fit coverage and a cap table built for the next round
Aligned, and simple.
- → Monthly retainer, paid upfront, month by month. No minimum term.
- → Success fee on capital raised, payable only on successful receipt of capital from investors we engaged.
credited back
→
Why not success-only? You don't pay an attorney only when they win, or a surgeon only when the operation succeeds. Asking us to absorb 100% of the downside risk on variables we don't control isn't a fee structure. It's a full transfer of risk.
The raise closed.
The company kept moving.
Send your case →
Any securities offered to or on behalf of U.S. Persons are being conducted pursuant to a chaperone arrangement under SEC Rule 15a-6 and through Finalis Securities LLC, Member FINRA and SIPC.